Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 713 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency MOST POPULAR News digest – dinosaur bone cancer, YouTube junk food ad ban... August 8, 2020 Giving Myself the Most Time and Best Chance at Beating Cancer:... October 10, 2023 Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint... December 9, 2020 ESMO Highlights the Importance of Prioritising the Fight Against Cancer in... September 10, 2025 Load more HOT NEWS Significant 20-Year Benefit of 2 Years of Adjuvant Goserelin and Tamoxifen... Working towards equal cancer care for everyone Cancer in My Community: Caring for Children With Cancer in Armenia Representation, retention and hope – how a mentorship scheme is helping...
